TFCP2L1 and neoplasm: Similar to the immunostaining results of tumor tissues from BC patients (Fig 4C and D), TFCP2L1‐expressing cells in xenograft samples showed a high concurrence with cells stained with the bladder CSC markers including CD44 (Fig 7F), KRT14, and SALL4 (Appendix Fig S8).